TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00210652
Drug: RWJ 333369:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
Study: NCT02637934
Drug: [18F]FluorThanatrace
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01424488
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
Study: NCT00239031
Drug: Enteric-Coated Mycophenolate Sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-Coated Mycophenolate Sodium
Study: NCT01494233
Drug: 250 mg LX1033 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg LX1033 tablets administered orally
Study: NCT01494233
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet administered orally
Study: NCT02550652
Drug: Mycophenolate Mofetil/Mycophenolic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF/MPA will be administered as per schedule specified in the respective arm.
Study: NCT03001895
Drug: 18F-DCFPyL PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-DCFPyL PET/CT
Study: NCT04284657
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40 mg QD
Study: NCT01337349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Pill 400mg taken orally three times a day for 6 months
Study: NCT00659503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05303688
Drug: iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The primary predictor variable was preventive analgesia group. Patients were randomly divided in two groups. 50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey) were administrated 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15
Study: NCT05303688
Drug: Steril Salin (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15) and iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15).
Study: NCT00559676
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00559676
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00559676
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04329494
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via PIPAC
Study: NCT04329494
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04380207
Drug: QPX7728
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic
Study: NCT04380207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT04380207
Drug: QPX2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic
Study: NCT00029731
Drug: Arginine hydrochloride
Normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00678561
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment once daily for 28 days
Study: NCT00678561
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment twice daily for 28 days
Study: NCT00678561
Drug: Placebo Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment once daily for 28 days
Study: NCT00678561
Drug: Placebo Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment twice daily for 28 days
Study: NCT04464642
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 25 mg subcutaneous is given in group A
Study: NCT03273036
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: no injected agent
Study: NCT01236404
Drug: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly injections for up to four weeks
Study: NCT01941953
Drug: Metformin and Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
Study: NCT04329494
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04547361
Drug: E2511
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: E2511 tablets.
Study: NCT04547361
Drug: E2511 Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching E2511 tablets.
Study: NCT03704610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial period with 2 injections with placebo allowing the determination of the primary criteria Then an extension with infliximab with 5 supplementary perfusions
Study: NCT01328002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets daily
Study: NCT02869971
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
Study: NCT01306617
Drug: ABT-450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT01306617
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT01494311
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
Study: NCT01494311
Drug: Subcutaneous injection of 0.5 ml Lidocain 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
Study: NCT01494311
Drug: Subcutaneous injection of saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
Study: NCT03049163
Drug: vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
Study: NCT00349492
Drug: IP
Normalized name: GIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan+cisplatin
Study: NCT02047604
Drug: SAN-300 0.5 mg/kg QW
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02047604
Drug: SAN-300 1.0 mg/kg QW
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02047604
Drug: SAN-300 2.0 mg/kg QOW
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02047604
Drug: SAN-300 4.0 mg/kg QOW
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02047604
Drug: SAN-300 4.0 mg/kg QW
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02047604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02381080
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
Study: NCT01976416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00216294
Drug: RG1068 (Synthetic Human Secretin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03135522
Drug: Zinc Acetate 50 Mg Oral Capsule
Normalized name: zinc acetate 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~* Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~* Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)
Study: NCT03135522
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Day 0 (randomization) to day 3 Placebo (one capsule per day)~* Day 4 to day 7 If well tolerated: placebo (two capsules per day)~* Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)
Study: NCT03281811
Drug: Aminolevulinic Acid Hydrochloride
Normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given topically
Study: NCT03281811
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo PDT
Study: NCT03436472
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline infusion
Study: NCT00885872
Drug: Rosuvastatin (Crestor)
Normalized name: rosuvastatin Oral Tablet [Crestor]
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
Study: NCT03779841
Drug: AGN-151607
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
Study: NCT03779841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
Study: NCT00672477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04466514
Drug: ASTX029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: tablet; Route of Administration: oral
Study: NCT01176591
Drug: Placebo session 1, Placebo session 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one per session, oral administration
Study: NCT00515333
Drug: TRx0014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard capsule; 60 milligrams; t.i.d.
Study: NCT00515333
Drug: TRx0014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard capsule; 30 milligrams; t.i.d.
Study: NCT00515333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard capsule; 0 milligrams; t.i.d.
Study: NCT00515333
Drug: TRx0014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard capsule, 100 milligrams, t.i.d.
Study: NCT00453765
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01221441
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraarticular injection of normal saline as a placebo control
Study: NCT01322204
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One single oral dose of 1 mg/kg of codeine
Study: NCT04147013
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
Study: NCT04147013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
Study: NCT00466193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
Study: NCT02944578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes.
Study: NCT01257204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, oral, 0 mg, once daily, for 24 weeks
Study: NCT01621399
Drug: Product 55394
Normalized name: Pyelocalyceal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product 55394 vaginal gel in a prefilled applicator.
Study: NCT01621399
Drug: Placebo Vehicle (non-treatment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vehicle vaginal gel in an applicator (placebo).
Study: NCT04622254
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT04622254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
Study: NCT02744846
Drug: Antibiotics exposure
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02575781
Drug: SAR428926
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
Study: NCT00004357
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01040429
Drug: Lactose capsula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1-56 (week 1-8): 1 capsula x 2/day for patients \< 35 kg; 2 capsula x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients \< 35 kg; 1 capsula x 2/day for patients \> 35 kg
Study: NCT02180425
Drug: Tretinoin or Adapalene
Normalized name: adapalene Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
Study: NCT00679991
Drug: PRT-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically to AVF during surgery
Study: NCT00679991
Drug: PRT-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation study. Drug/placebo administered at the time of fistula creation
Study: NCT00323739
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 10 mg by mouth daily
Study: NCT00456092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT00068055
Drug: Omr-lgG-am
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
Study: NCT00068055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline.
Study: NCT02472665
Drug: plasma-derived FVIII/VWF concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
Study: NCT01312402
Drug: Placebo in 5 mL dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
Study: NCT00009230
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02660736
Drug: Placebo Liquid Auto-injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
Study: NCT02660736
Drug: Placebo Lyophilized DCC Pen injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
Study: NCT04412902
Drug: adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy and/or radiotherapy
Study: NCT01540227
Drug: Regular Treatment for Syphilis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes
Study: NCT00563797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: NCT03586869
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03586869
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03586869
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03586869
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study: NCT01198184
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00812929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
Study: NCT00812929
Drug: GSK2190915
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
Study: NCT01070927
Drug: RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg po daily, 3 days on 4 days off schedule
Study: NCT01070927
Drug: RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
Study: NCT01646671
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 200 mg tablet once daily
Study: NCT01646671
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
Study: NCT01646671
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
Study: NCT02359292
Drug: CHF 5993 HS 200/6/25 pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02359292
Drug: CHF 5993 MS 100/6/25 pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02359292
Drug: CHF 5993 HS 200/6/25 pMDI + Charcoal Block
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02359292
Drug: CHF 5993 MS 100/6/25 pMDI + Charcoal Block
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02359292
Drug: Placebo pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02443298
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for risankizumab
Study: NCT05846009
Drug: SAR442501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05846009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT01116089
Drug: Bramitob® administered by PARI LC® PLUS nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: (tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
Study: NCT01116089
Drug: Bramitob® administered by PARI eFlow® rapid electronic nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: (tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
Study: NCT00237952
Drug: EDTA chelating agents
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01991834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of saline sterile solution
Study: NCT00647855
Drug: Levothyroxine Sodium Tablets 300 μg
Normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2x300mcg, single dose fasting
Study: NCT00647855
Drug: Synthroid® Tablets 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x300mcg, single dose fasting
Study: NCT03610490
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04096560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-994 placebo-matching tablets.
Study: NCT03204942
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
Study: NCT00103792
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
Study: NCT02791334
Drug: LY3300054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02791334
Drug: LY3321367
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV